2016年皇后镇分子生物学（上海）会议

【会议嘉宾】

No.	Speaker	Organization	Title
	Plennary session
1	Aaron Ciechanover （2004 Nobel Laureate in Chemistry）	Technion – Israel Institute of Technology, Haifa, Israel	The ubiquitin proteolytic system: from basic mechanisms thru human diseases and on to drug targeting
2	Jens Juul Holst	University of Copenhagen, Copenhagen, Denmark	Recent developments regarding GLP-1 based therapies for type 2 diabetes
3	Kevan M. Shokat	University of California San Francisco, San Francisco, U.S.A.	Non-traditional strategies for drugging traditional targets
4	Shaomeng Wang	University of Michigan, Ann Arbor, U.S.A.	Targeting protein-protein interactions for new cancer therapeutics
	Parallel sessions
5	Andrew D. Abell	The University of Adelaide, Adelaide, Australia	Rational and in situ target driven inhibitor optimisation: new protease inhibitors and antibiotics
6	Jung-Mo Ahn	The University of Texas at Dallas, Richardson, U.S.A.	Rational design of alpha-helix mimetics for inhibiting protein-protein interactions
7	Ross Bathgate	Florey Institute of Neuroscience and Mental Health, Melbourne, Australia	Targeting complex peptide G protein-coupled receptors with peptide and small molecule ligands
8	Charlie M. Boone	University of Toronto, Toronto, Canada	Global mapping of genetic and chemical-genetic networks
9	Jean A. Boutin	Institut de Recherches Servier, Paris, France	Quinone reductase 2 - 30 years of wondering what it does
10	Margaret Brimble	University of Auckland, Auckland, New Zealand	The role of medicinal chemistry in the search for therapeutic agents: natural products vs. peptides
11	Li Chen	Hua Medicine, Shanghai, China	Discovery and development of first-in-class type 2 diabetes therapy in China for the world
12	Sun Choi	Ewha Womans University, Seoul, Korea	Exploration of protein motion, allosteric hot spots, and multiple signaling pathways inside GPCR structures, and its application to drug design
13	Greg Cook	University of Otago, Dunedin, New Zealand	Targeting mycobacterial energetics to produce new tuberculosis drugs
14	Peter Crack	The University of Melbourne, Melbourne, Australia	The role of type-1 interferon signalling in the control of neuroinflammation
15	Simon L. Croft	London School of Hygiene and Tropical Medicine, London, U.K.	Challenges and opportunities for the development of new treatments for leishmaniasis
16	Bill Denny	Auckland Cancer Society Research Centre, Auckland, New Zealand	Use of CBI-based antibody-drug conjugates for cancer therapy
17	Rod Dunbar	Maurice Wilkins Centre, Auckland, New Zealand	Synthetic vaccines to stimulate T cells
18	Gary Evans	Victoria University of Wellington, Lower Hutt, New Zealand	Drug discovery through intelligent design
19	Jian-Bing Fan	AnchorDx Corporation, Guangzhou, China	Advancing cancer research through genomics technology evolution
20	Fang Fang	Abimmune Biopharma, Inc., San Diego, U.S.A.	From a pure concept to a first-in-class live saving drug and more
21	Jack Flanagan	Strategies for inhibiting lipid kinases	University of Auckland, Auckland, New Zealand
22	Yong Gan	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	Functional particle design for oral insulin delivery: challenges and opportunities
23	Ian Gilbert	University of Dundee, Dundee, U.K.	Drug discovery for neglected diseases
24	Zeguang Han	Shanghai Jiaotong University, Shanghai, China	Identification of therapeutic targets for liver cancer through genomic and epigenomic approaches
25	Debbie Hay	University of Auckland, Auckland, New Zealand	Towards novel amylin mimetics for diabetes and obesity
26	Simon Hinkley	Victoria University of Wellington, Lower Hutt, New Zealand	Application of heparan sulfate to facilitate bone repair
27	Wanjin Hong	Institute of Molecular and Cell Biology, A*STAR, Singapore	Targeting the Hippo pathway for novel cancer therapy
28	Ai-Jun Hou	Fudan University, Shanghai, China	Natural products as important source of drug discovery and development
29	Daniel Hoyer	The University of Melbourne, Melbourne, Australia	5-HT receptors in health and disease: recent clinical developments
30	Baolai Hua	Peking Union Medical College Hospital, Beijing, China	The pathophysiology of hemophiliac arthropathy: knowledge from animal model and  patients
31	David Huang	Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia	Targeting the BCL2-regulated pathway to cell death
32	Chen Jiang	Fudan University, Shanghai, China	Nanotechnology-based drug delivery systems targeting to glioma
33	Hualiang Jiang	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	Drug discovery from traditional Chinese medicine
34	Sheng Jiang	Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China	Discovery of novel class I histone deacetylase inhibitors through total synthesis of natural products
35	Jason Gang Jin	Cloud Health Genomics Ltd., Shanghai, China	Whole genome sequencing and precision medicine in China
36	Jian Jin	Icahn School of Medicine at Mount Sinai, New York, U.S.A.	Discovery of selective inhibitors for histone methyltransferases
37	Kazuya Kikuchi	Osaka University, Osaka, Japan	Protein labeling by functional probes for imaging protein localization "log"
38	Sunghoon Kim	Seoul National University, Seoul, Korea	Chemical intervention of oncogenic protein-protein interactions
39	Ho Jeong Kwon	Yonsei University, Seoul, Korea	Integrative approach of drug and target discovery towards translational studies
40	Jesper Lau	Novo Nordisk A/S, Copenhagen, Denmark	Design of long-acting GLP-1 analogs applicable for once weekly and oral dosing
41	Weidong Le	Dalian Medical University, Dalian, China	Nurr1: a new research target for the pathogenesis and therapy of Parkinson’s disease
42	Jung Weon Lee	Seoul National University, Seoul, Korea	Dissemination from colon cancer spheroids in 3D extracellular matrix gel environment
43	Kyeong Lee	Dongguk University, Seoul, Korea	Targeting tumor microenvironment in the search for novel anticancer therapeutics
44	Cong Li	Fudan University, Shanghai, China	Brain drug delivery by tuning blood brain barrier permeability
45	Jingya Li	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	Discovery of novel glucose-lowering therapeutics targeting to mitochondria uncoupling
46	Sheena Li	RIKEN Institute, Wako, Japan	Unbiased functional annotation of compound libraries using yeast chemical genomics
47	Jiayu Liao	University of California, Riverside, U.S.A.	Development of quantitative and sensitive FRET technology platform for biomedical and pharmaceutical applications
48	Pentao Liu	The Wellcome Trust Sanger Institute, Cambridge, U.K.	Establishment of cultures of expanded potential stem cells
49	Vish Nene	International Livestock Research Institute, Nairobi, Kenya	Supporting bovine vaccine development through reverse genomic approaches
50	Gavin Painter	Victoria University of Wellington, Lower Hutt, New Zealand	Synthetic vaccines that utilize innate-like T cell help
51	Christopher Proud	South Australian Health and Medical Research Institute, Adelaide, Australia	Roles of the MAP kinase-interacting kinases in metabolic diseases
52	Kirstine Roepstorff	Novo Nordisk A/S, Copenhagen, Denmark	Biomarkers in haemophilic arthropathy
53	Mette Rosenkilde	University of Copenhagen, Copenhagen, Denmark	Design of high-affinity ligands for the GIP receptor
54	Patrick Sexton	Monash University, Melbourne, Australia	An evolving view of class B GPCR signalling
55	Peter Shepherd	University of Auckland, Auckland, New Zealand	The future for kinase inhibitors
56	David R. Sherman	Center for Infectious Disease Research, Seattle, U.S.A.	Old dog, new tricks: updated approaches for tuberculosis drug discovery
57	Leming Shi	Fudan University, Shanghai, China	Big data, precision medicine, and the MAQC project
58	Wenqing Shui	Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin, China	Mixture-based ligand discovery against therapeutic protein targets by affinity MS
59	Yi Sun	Zhejiang University, Hangzhou, China	SAG E3 ubiquitin ligase is a valid lung cancer target: Therapeutic intervention
60	Roger K. Sunahara	University of Toronto, Toronto, Canada	GPCRs, powerful allosteric switches to regulate G proteins and cell signaling
61	Wei Tang	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	Development of artemisinin analog in the treatment of autoimmune disease
62	Paul Teesdale-Spittle	Victoria University of Wellington, Lower Hutt, New Zealand	Development of a new class of protein trafficking inhibitors
63	Motonari Uesugi	Institute for Chemical Research, Kyoto University, Kyoto, Japan	Synthetic molecules for cell therapy
64	Yasuteru Urano	University of Tokyo, Tokyo, Japan	Novel intramolecular spirocyclization-based fluorogenic probes: from in vivo imaging of tiny tumors to super-resolution imaging
65	Peter K. Vogt	The Scripps Research Institute, La Jolla, U.S.A.	MYC and the non-coding transcriptome
66	Yonghui Wang	Fudan University, Shanghai, China	Discovery of novel RORgT modulators
67	Paul Watkins	Neurotar Ltd., Helsinki, Finland	Effective technology transfer in translational medicine: challenges, complexities and opportunities
68	Bo Wiinberg	Novo Nordisk A/S, Copenhagen, Denmark	Plant-based oral tolerance to haemophilia therapy
69	Denise Wootten	Monash University, Melbourne, Australia	Molecular mechanisms that govern biased agonism at Class B GPCRs
70	Beili Wu	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	Structural studies of human purinergic receptor P2Y1R
71	Jane Y. Wu	Northwestern University Feinberg School of Medicine, Chicago, U. S.A.	RNA binding proteins in neurodegenerative disorders
72	Yi-Long Wu	Sun Yat-sen University, Guangzhou, China	Innovative clinical studies on lung cancer in China
73	Yundong Wu	Peking University Shenzhen Graduate School, Shenzhen, China	Structural understandings of disease-causing mutations of WD40 proteins
74	Jiang Xia	The Chinese University of Hong Kong, Hong Kong SAR, China	Reactive peptide to probe the biology of adaptor proteins in cells
75	Rui-Ping Xiao	Peking University, Beijing, China	Role of E3 in metabolic syndrome
76	Xin Xie	The National Center for Drug Screening, Shanghai, China	G protein-coupled receptors as therapeutic targets for multiple sclerosis
77	Huaqiang Xu	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	An X-ray laser structure of rhodopsin-arrestin complex
78	Xiao Xu	Acea Bioscienecs, Inc., San Diego, U.S.A.	Novel platform system that facilitates drug development of cancer immnunotherapy
79	Renchi Yang	National Hemophilia Registry Center of China, Tianjin, China	Current situation and issues in hemophilia care in China
80	Yonghua Yang	Fudan University, Shanghai, China	The pons asinorum for the discovery of hsp90 inhibitor: K292 acetylation in hsp90
81	Zhen Yang	Peking University Shenzhen Graduate School, Shenzhen, China	A novel type of Rh-catalyzed [3+2] cycloaddition: application to the total synthesis of complex natural products
82	Richard D. Ye	University of Macau,  Macau SAR, China	Identification of SAA as a regulator of inflammation and immunity
83	Andrew A. Young	Intarcia Therapeutics, Inc., Research Triangle Park, NC, U.S.A.	Optimization of peptide therapeutics for convenient delivery
84	Ker Yu	Fudan University, Shanghai, China	Role of lipid metabolism in targeted cancer therapy
85	Qiang Zhao	Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China	The crystal structures and functional implications of P2Y12R
	Young Investigators Forum
86	Masayoshi Arai	Osaka University, Osaka, Japan	Exploring novel drug target for cancer chemotherapy by the study of furospinosulin-1, a hypoxia-selective growth inhibitor of cancer cells
87	Kosuke Dodo	RIKEN Institute, Wako, Japan	Turn-ON fluorescent affinity labeling using small bifunctional O-NBD unit
88	Yan Li	Fudan University, Shanghai, China	Functionalized nancomposites for analysis of trace components in complex biosamples
89	Wei Lu	Fudan University, Shanghai, China	Photothermal nanoparticles for biomedical application
90	Shinichi Sato	Kyoto University, Kyoto, Japan	Live-cell imaging of endogenous mRNAs with a small molecule
91	Xiaoyan Shen	Fudan University, Shanghai, China	Targeting macrophage function:role of sorting nexing 10 in immuno-inflammatory disease
92	Xiao-Hui Wang	Chemical Biology Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China	The neuroimmunopharmacology of opioids and the CNS drug discovery
93	Ying Wang	University of Macau,  Macau SAR, China	Andrographolide analogs as novel inhibitors to toll-like receptor signaling pathway
94	Lu Zhou	Fudan University, Shanghai, China	Targeting cancer metabolism: glycolytic enzyme PGAM1 inhibitors as anti-cancer agents

【会议门票】

注册费：2000元/人（学生凭学生证注册享半价优惠1000元/人），仅适用于正式报名并作预付的参会者，现场支付按下述标准收取。

逾期报名：

2016年2月16日至2月29日，注册费2500元/人，学生1250元/人。

2016年3月1日至3月16日，注册费3000元/人，学生1500元/人。

2016年3月17日至3月18日（现场注册），4000元/人，学生2000元/人。

【会议通知】

国家新药筛选中心作为新西兰皇后镇分子生物学会议机构的合作方，自2013年3月以来已经连续三年成功举办了皇后镇分子生物学（上海）会议，现定于2016年3月17日至3月18日在上海举行主题为“药物发现与转化医学”（Drug Discovery and Translational Medicine）的2016年皇后镇分子生物学（上海）会议，并同时召开第八届全国药物筛选新技术研讨会和中国热带病药物与诊断创新网络第五次会议。 

中国热带病药物与诊断创新网络（China NDI）是在联合国儿童基金会、联合国计划开发署、世界银行及世界卫生组织热带病研究与培训特别规划署的资助下于2009年10月由中国疾病预防控制中心寄生虫病研究所、国家新药筛选中心和第二军医大学等12家单位在上海发起成立的，旨在为我国乃至亚太地区的热带病防控做出贡献。 

皇后镇分子生物学会议（Queenstown Molecular Biology Meetings）是国际知名的品牌学术论坛，长期以来吸引了无数科学家、研究生和创新创业人士的参加，加上与之同步举行的药物筛选新技术研讨会将为国内在新药发现领域从事研究、开发、投资和并购的专业人员提供最新的动态信息和广泛的交流平台。本次会议已经邀请了一批著名的科学家、临床医生、企业家和投资家参会演讲，他们来自澳大利亚、加拿大、中国、丹麦、芬兰、法国、以色列、日本、韩国、肯尼亚、中国香港、中国澳门、新西兰、新加坡、美国和英国等16个国家或地区。在目前已经确认的演讲人中包括两位诺贝尔奖获得者（Roger D. Kornberg教授和Aaron Ciechanover教授，名单见附）。 

本次活动得到国家卫计委“重大新药创制”科技重大专项课题管理办公室、中国金融信息中心（新华社）、中国科学院上海药物研究所、新西兰莫里斯•威尔金斯中心、浦东新区科协、张江高科技园区管委会和上海市研发公共服务平台等的支持，由复旦大学药学院、中国疾病预防控制中心寄生虫病研究所和上海市浦东新区工程师协会共同协办。2016年的会议将限制参会人数，请尽快报名。

会议名称： 2016年皇后镇分子生物学（上海）会议

会议时间：2016年3月17日至18日 

会议地点：中国金融信息中心（地址：上海市陆家嘴东园路18号）